Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Gliomas, the most common malignant primary brain tumours, remain universally lethal. Yet,
seminal discoveries in the past 5 years have clarified the anatomy, genetics and function of …

To follow the revision of the fourth edition of WHO classification and the recent progress on
the management of diffuse gliomas, the joint guideline committee of Chinese Glioma …

Molecular targeted therapies are revolutionized therapeutics which interfere with specific
molecules to block cancer growth, progression, and metastasis. Many molecular targeted …

Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR
deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole …

Tumor Treating Fields (TTFields), an approved therapy for glioblastoma (GBM) and
malignant mesothelioma, employ noninvasive application of low-intensity, intermediate …

Glioblastoma (GBM) is a rare tumor and one of the most challenging malignancies to treat in
all of oncology. Although advances have been made in the treatment of GBM, encouraging …

Introduction Glioblastoma is a very aggressive cancer with dismal prognosis despite
standard of care including surgical resection, radiation therapy, and chemotherapy. There is …

Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light
of the multitude of recent phase III trials that have failed to meet their primary endpoints …